Tarlatamab, Tarlatamab
CSET 2024/4014
Phase 2 small_molecule active
Quick answer
Tarlatamab, Tarlatamab for Metastaic small cell lung cancer (SCLC) and other poorly differentitated neuroendocrine carcinomas (NECs) is a Phase 2 program (small_molecule) at The George Institute with 1 ClinicalTrials.gov record(s).
Program details
- Company
- The George Institute
- Indication
- Metastaic small cell lung cancer (SCLC) and other poorly differentitated neuroendocrine carcinomas (NECs)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active